EFM
BBIO icon

E Fund Management’s BridgeBio Pharma BBIO Stock Holding History

E Fund Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$452K Sell
6,070
-2,092
-26% -$147K 0.01% 297
2026
Q1 		$606K Buy
+8,162
New +$592K 0.02% 241
2025
Q2 		$948K Buy
21,965
+3,075
+16% +$112K 0.05% 175
2025
Q1 		$653K Buy
18,890
+1,105
+6% +$37.3K 0.03% 202
2024
Q4 		$488K Buy
17,785
+2,151
+14% +$55.6K 0.02% 232
2024
Q3 		$398K Sell
15,634
-862
-5% -$22.6K 0.02% 221
2024
Q2 		$418K Buy
16,496
+1,785
+12% +$48.8K 0.02% 194
2024
Q1 		$455K Sell
14,711
-58
-0.4% -$1.97K 0.03% 170
2023
Q4 		$596K Sell
14,769
-1,326
-8% -$39.8K 0.04% 129
2023
Q3 		$424K Sell
16,095
-11,821
-42% -$335K 0.03% 156
2023
Q2 		$480K Buy
27,916
+12,700
+83% +$191K 0.04% 118
2023
Q1 		$252K Sell
15,216
-18,610
-55% -$217K 0.02% 261
2022
Q4 		$258K Buy
33,826
+476
+1% +$4.56K 0.02% 253
2022
Q3 		$331K Sell
33,350
-18,598
-36% -$193K 0.03% 219
2022
Q2 		$472K Buy
51,948
+20,684
+66% +$173K 0.04% 153
2022
Q1 		$317K Buy
+31,264
New +$321K 0.01% 183

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

E Fund Management's BBIO Position: Q2 2026 in Review

E Fund Management reduced its BridgeBio Pharma (BBIO) stake by 26% in Q2 2026, selling an estimated $147K and leaving 6,070 shares worth $452K. The position accounts for 0.01% of the portfolio, ranked #297.

E Fund Management first reported a position in BBIO in Q1 2022 and has held it in 16 quarters since. The position peaked at $948K in Q2 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • E Fund Management held 6,070 shares of BridgeBio Pharma worth $452K as of Q2 2026.
  • E Fund Management sold 2,092 BridgeBio Pharma shares in Q2 2026, an estimated $147K.
  • BridgeBio Pharma made up 0.01% of E Fund Management's portfolio in Q2 2026, its #297 holding.
  • E Fund Management first reported a position in BridgeBio Pharma in Q1 2022 and has held it in 16 quarters since.
  • E Fund Management's BridgeBio Pharma position peaked at $948K in Q2 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.